New research at Tel Aviv University offers significant hope of curing the most aggressive and presently incurable blood cancer called mantle cell lymphoma (MCL) and others like it. The promising and innovative system was found to successfully halt the proliferation of a cancer-related protein in white blood cells in both animal models and samples taken from MCL patients.
The study has just been published in the early edition of the Proceedings of the [US] National Academy of Sciences.
The research was led by Prof. Dan Peer of TAU ’s department of cell research and immunology and conducted by TAU doctoral students Shiri Weinstein and Itai Toker, in collaboration with Prof. Pia Raanani of Rabin Medical Center-Beilinson Campus in Petah Tikva and Prof. Arnon Nagler of Sheba Medical Center at Tel Hashomer.
With a median survival rate of just five to seven years, MCL is considered deadly and available therapies are scarce. Some 3,000 Americans and a few dozen Israelis are diagnosed with it in an average year.
Despite progress in personalized therapies to treat metastases elsewhere in the body, systemic therapeutic drug delivery to cancerous blood cells continues to challenge the world of cancer research.